



Cite this: RSC Adv., 2022, 12, 20199

 Received 29th April 2022  
 Accepted 7th July 2022

 DOI: 10.1039/d2ra02722d  
 rsc.li/rsc-advances

## Copper-catalyzed three-component reaction to synthesize polysubstituted imidazo[1,2-a]pyridines†

 Zitong Zhou,<sup>a</sup> Danyang Luo,<sup>a</sup> Guanrong Li,<sup>a</sup> Zhongtao Yang,<sup>a</sup> Liao Cui<sup>\*a</sup> and Weiguang Yang<sup>ID \*abc</sup>

An efficient three-component one-pot and operationally simple cascade of 2-aminopyridines with sulfonyl azides and terminal yrones is reported, providing a variety of polysubstituted imidazo[1,2-a]pyridine derivatives in moderate to excellent yields. In particular, the reaction goes through CuAAC/ring-cleavage process and forms a highly active intermediate  $\alpha$ -acyl-*N*-sulfonyl ketenimine with base free.

Polysubstituted imidazo[1,2-a]pyridines are well established as privileged scaffolds which are commonly encountered in many bioactive natural products and biological molecules that may be good drug candidates.<sup>1</sup> Most imidazo[1,2-a]pyridines possess various biological activities, like antibacterial,<sup>2</sup> antiinflammatory,<sup>3</sup> antiviral,<sup>4</sup> and anticancer.<sup>5</sup> Some of the imidazo[1,2-a]pyridine derivatives are commercially available drugs, including Saripidem,<sup>6</sup> Alpidem,<sup>7</sup> Zolpidem,<sup>8</sup> Zolimidine,<sup>9</sup> Miroprofen<sup>10</sup> and drug candidates GSK812397 (Fig. 1).<sup>11</sup> Therefore, the development of novel methods for the synthesis of these imidazo[1,2-a]pyridines is important in the field of synthetic organic and pharmaceutical chemistry.

In the past few years, reactions utilizing Cu,<sup>12</sup> Pd,<sup>13</sup> Mn,<sup>14</sup> TEMPO-mediated,<sup>15</sup> I<sub>2</sub> (ref. 16) and a few other catalysts<sup>17</sup> have provided attractive and valuable routes for the construction of imidazo[1,2-a]pyridines. However, most reactions can only produce monosubstituted imidazo[1,2-a]pyridines or halogenated intermediates (Scheme 1a)<sup>18</sup> which can undergo one more steps of coupling reaction leading to polysubstituted products. Therefore, developing one-pot synthetic reactions will provide a direct and powerful tool to meet these challenges. To the best of our knowledge, imidazo[1,2-a]pyridines can be synthesized from 2-aminopyridines, terminal alkyne and aldehyde in a three-component coupling reaction, catalyzed by copper, in one pot (Scheme 1b).<sup>19</sup> However, aldehydes are unstable and easily oxidized. They are environmentally unfriendly for

synthesis or complex procedures. Under this background, the development of multicomponent one-pot synthetic strategies for the preparation of polysubstituted imidazo[1,2-a]pyridines still remains highly desirable.

Previous studies reported that the copper-catalyzed multicomponent reactions (MCRs) of sulfonyl azides, terminal alkynes and other components (CuAAC/ring-cleavage reaction) has been applied to synthesize numerous oxygen- and nitrogen-containing heterocyclic compounds.<sup>20</sup> However, the reaction generally carried out under strong base conditions, and limited the application of some substrates, such as terminal yrones, which will take a self-condensation under the base conditions.<sup>21</sup> Thus, the neutral or weak acidic conditions have developed by our group and the terminal yrones successfully used in CuAAC/ring-cleavage reaction to form a highly active intermediate  $\alpha$ -acyl-*N*-sulfonyl ketenimines.<sup>22</sup> Accordingly, an efficient one-pot and operationally three-component reaction of 2-aminopyridines, sulfonyl azides and terminal yrones is reported (Scheme 1c).

Our initial study began with an examination of the synthesis of imidazo[1,2-a]pyridine **4a** from 2-aminopyridine (**1a**), ethyl




Fig. 1 Some imidazo[1,2-a]pyridine drugs or drug candidates.

<sup>a</sup>Public Service Platform of South China Sea for R&D Marine Biomedicine Resources, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, 524023, China. E-mail: cuijiao@163.com; 09ywg@163.com


<sup>b</sup>The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, Guangdong, 524023, China

<sup>c</sup>Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, Guangdong, 524023, China

† Electronic supplementary information (ESI) available. CCDC 2121234. For ESI and crystallographic data in CIF or other electronic format see <https://doi.org/10.1039/d2ra02722d>



Previous work:




Scheme 1 Synthesis of polysubstituted imidazo[1,2-a]pyridines.

propiolate (**2a**) and *p*-tosyl azide (**3a**). Initial screenings involved using CuI as catalyst and no additive with a variety of solvents in a range of standard solvents. These results revealed that the desired conversion could be effected in most solvents (Table 1, entries 1–9), with EtOH delivering product **4a** in highest yield (83%). The other solvents give a comparable yields, such as DCE, toluene, MeCN and THF, while the DMSO and DMF gave the **4a** lowest yield of 26% and 35%. Thus, the optimal solvent was determined to be EtOH. Encouraged by this promising result, variety of catalysts were screened. Among the copper catalysts used, most Cu-catalysts exhibited the high catalytic reactivity in this reaction whether it's Cu<sup>I</sup>-catalysts or Cu<sup>II</sup>-catalysts (Table 1, entries 10–13). However, Cu(OTf)<sub>2</sub> exhibited low efficiencies for this reaction, and other catalysts, such as AgOAc failed to produce the desired product (Table 1, entries 14

Table 1 Optimization of catalytic conditions<sup>a</sup>

Entry	Cat.	Solvent	Yield <sup>b</sup> (%) <b>4a</b>
1	CuI	CHCl <sub>3</sub>	74
2	CuI	DCE	77
3	CuI	Toluene	78
4	CuI	MeCN	80
5	CuI	THF	62
6	CuI	1,4-Dioxane	44
7	CuI	DMSO	26
8	CuI	DMF	35
9	<b>CuI</b>	<b>EtOH</b>	<b>83</b>
10	CuCl	EtOH	75
11	CuBr	EtOH	73
12	CuBr <sub>2</sub>	EtOH	70
13	Cu(OAc) <sub>2</sub>	EtOH	50
14	Cu(OTf) <sub>2</sub>	EtOH	32
15	AgOAc	EtOH	nd <sup>c</sup>
16	CuI	EtOH	80 <sup>d</sup>
17	CuI	EtOH	76 <sup>e</sup>

<sup>a</sup> Reaction conditions: **1a** (1.0 mmol), cat. (10 mol%) in the solvent (3 mL) was added **2a** (1.5 mmol) and **3a** (1.5 mmol) stirring at 80 °C for 6 h. <sup>b</sup> Isolated yields. <sup>c</sup> nd = not detected the target product. <sup>d</sup> The reaction temperature was 70 °C. <sup>e</sup> The temperature was 90 °C.

Table 2 Substrate scopes<sup>a</sup>


<sup>a</sup> Unless otherwise noted, the reaction conditions were as follow: **1** (1.0 mmol), CuI (10 mol%) in the MeCN (3 mL) was added **2** (1.5 mmol), **3** (1.5 mmol) stirring at 80 °C for 6 h.

and 15). Lastly, the effect of temperature was evaluated. Screening results revealed that the reaction temperature above or below 80 °C decreased the reaction yield (Table 1, entries 16 and 17).

Under the optimized conditions (Table 1, entries 9), the capacity of this reaction to affect the coupling of a range of different substrates was investigated. Agreeably, as shown in Table 2, various 2-aminopyridines, with an alkyl group or methoxy group, all exhibited good functional group tolerance to obtain the desired products (**4a**–**4c**, **4e**). However, the 2-aminopyridines with electron-withdrawing nature can't obtain the desire products. In addition, due to steric hindrance, some 2-aminopyridines obtained the products with low yield or cannot be separated to obtain the desired products. Such as 6-ethyl-2-aminopyridine (**1d**) obtained the product **4d** with low yield and 6-methyl-2-aminopyridine (**1f**) or 6-methoxy-2-aminopyridine (**1g**) obtained the uncyclized products **4s** and **4t**.

Next, the scope and limitation of the terminal ynone **2** and sulfonyl azide **3** substrates were tested. It is noteworthy that the sulfonyl azide substrates showed slight influences on this reaction. With R<sup>3</sup> changed by aromatic or aliphatic substituents, such as -Ph, -(4-ClC<sub>6</sub>H<sub>4</sub>), -(4-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>), -(4-OMeC<sub>6</sub>H<sub>4</sub>), -Me and -n-Bu, the reaction could smoothly give the anticipated products (**4f**–**4n**) in comparable yields. The substrates R<sup>2</sup> bearing the -OMe, -O'Bu, -Me and other alkyl group also can obtain **4o**–**4r** in good yields.






Scheme 2 Investigation of the reaction of 2-aminopyridine (**1a**), aryl acetylenes (**2f**, **2g**) and *p*-tosyl azide (**3a**).

In order to broaden the suitability of substrates, we also investigated other terminal alkynes, such as aryl acetylenes. The experiments revealed that some aryl acetylene such as 3-methyl phenylacetylene can obtain imidazo[1,2-*a*]pyridine **4u** with low yield of 26% and an uncyclized linear product **4v** (Scheme 2a). Most aryl acetylenes such as 4-methoxy phenylacetylene only obtain uncyclized products (Scheme 2b). It shows that the reactivity of terminal yrones is higher than that of traditional terminal alkyne.

None of the product imidazo[1,2-*a*]pyridines **4a**–**4r** have been reported previously, which were subject to full spectroscopic characterization (see ESI† for details) and the derived data were in complete accord with the assigned structures. And **4a** was confirmed by single-crystal X-ray analysis (Fig. 2).

A possible reaction pathway for the formation of imidazo[1,2-*a*]pyridine (**4a**) from precursors **1a**, **2a** and **3a** is shown in Scheme 3. Thus, in keeping with earlier proposals,<sup>19,21</sup> the substrates **2a** and **3a** are expected to react, in the presence of the copper(i) catalyst to form the metallated triazole **A** through the CuAAC procedure. Then, the complex **A** undergo a ring-cleavage rearrangement leading to a highly active intermediate *N*-sulfonyl- $\alpha$ -acylketenimine **B**. This last species **B** is captured by **1a** via nucleophilic addition to generate the intermediate **C**, which deliver the observed product **4a** by intramolecular oxidative coupling similar to literature.<sup>23</sup> Otherwise, due to the poor activity, most of the traditional terminal alkynes involved in the reaction will stop in the intermediate **C** leading the uncyclized products.

In summary, we have developed an original approach for the synthesis of polysubstituted imidazo[1,2-*a*]pyridines from a mixture of the corresponding 2-aminopyridines, sulfonyl azides and terminal yrones, through CuAAC/ring-cleavage



Scheme 3 Plausible reaction mechanism.

process and generated a highly active intermediate *N*-sulfonyl ketenimine. More detailed novel reactions and the investigation of new applications of this intermediate are now being undertaken in our laboratory.

## Experimental

### General

All melting points were determined on a Yanaco melting point apparatus and were uncorrected. IR spectra were recorded as KBr pellets on a Nicolet FT-IR 5DX spectrometer. All spectra of  $^1\text{H}$  NMR (400 MHz) and  $^{13}\text{C}$  NMR (100 MHz) were recorded on a JEOL JNM-ECA 400 spectrometer in DMSO-d<sub>6</sub> or CDCl<sub>3</sub> (otherwise as indicated) with TMS was used as an internal reference and *J* values are given in Hz. HRMS were obtained on a Thermo Scientific Q Exactive Focus Orbitrap LC-MS/MS spectrometer.

### Preparation and characterizations of compounds **4a**–**4x**

Ethyl-2-((4-methylphenyl)sulfonamido)imidazo[1,2-*a*]pyridine-3-carboxylate (**4a**). To a solution of CuI (19.5 mg, 0.10 mmol) in EtOH (3 mL) was added pyridin-2-amine (**1a**, 94.2 mg, 1 mmol), ethyl propiolate (**2a**, 147 mg, 1.5 mmol), TsN<sub>3</sub> (295.8 mg, 1.5 mmol). After the mixture was stirred at 80 °C for 6 h (monitored by TLC), the solvent was removed. The residue was purified via flash chromatography (silica gel, 25% EtOAc in petroleum ether) to give of product **4a** (298.2 mg, 83%) as a white solid, m.p. = 155–157 °C ( $R_f$  = 0.3 in 1 : 3 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.94 (s, 1H), 8.80 (s, 1H), 8.07 (d, *J* = 8.4 Hz, 2H), 7.59 (d, *J* = 8.8 Hz, 1H), 7.37 (t, *J* = 8.0 Hz, 1H), 7.27 (d, *J* = 7.2 Hz, 2H), 6.95 (t, *J* = 6.8 Hz, 1H), 4.48–4.43 (m, 2H), 2.37 (s, 3H), 1.44 (t, *J* = 7.2, 3H);  $^{13}\text{C}$  NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.4, 149.0, 146.0, 144.2, 136.8, 129.4 (2C), 128.5, 128.2 (2C), 127.9, 117.0, 114.1, 100.3, 61.0, 21.6, 14.7; IR (KBr)  $\nu$  3257, 2308, 1656, 1550, 1435, 1336, 1220, 1165, 1089 cm<sup>-1</sup>; HRMS (ESI-TOF) (*m/z*). Calcd for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 360.1013, found 360.1006.




Fig. 2 Single-crystal X-ray analysis of **4a** (CCDC 2121234).†



**The products 4b–4x were prepared by the similar procedure**

Ethyl-8-methyl-2-((4-methylphenyl)sulfonamido)imidazo[1,2-a]pyridine-3-carboxylate (**4b**) (242.7 mg, 65%), white solid, m.p. = 151–152 °C ( $R_f$  = 0.25 in 1 : 4 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.78 (s, 1H), 8.68 (s, 1H), 8.14 (d,  $J$  = 8.0 Hz, 2H), 7.27 (d,  $J$  = 8.0 Hz, 2H), 7.15 (d,  $J$  = 6.8 Hz, 1H), 6.83 (t,  $J$  = 6.8 Hz, 1H), 4.40–4.46 (m, 2H), 2.55 (s, 3H), 2.37 (s, 3H), 1.43 (t,  $J$  = 7.0 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  160.6, 148.4, 146.0, 144.2, 136.7, 129.1 (2C), 128.9 (2C), 127.6, 126.7, 125.6, 113.9, 100.5, 60.9, 21.7, 16.7, 14.7; IR (KBr)  $\nu$  2974, 1654, 1544, 1446, 1359, 1236, 1163, 1087, 1056  $\text{cm}^{-1}$ ; HRMS (ESI) (*m/z*). Calcd for  $\text{C}_{18}\text{H}_{19}\text{N}_3\text{O}_4\text{S}$ ,  $[\text{M} + \text{H}]^+$  374.1169, found 374.1162.

Ethyl-7-ethyl-2-((4-methylphenyl) sulfonamido) imidazo[1,2-a] pyridine-3-carboxylate (**4c**) (333.0 mg, 86%), yellow solid, m.p. = 109–111 °C ( $R_f$  = 0.33 in 1 : 3 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.81 (s, 2H), 8.06 (d,  $J$  = 7.6 Hz, 2H), 7.39 (s, 1H), 7.27 (d,  $J$  = 7.6 Hz, 2H), 6.80 (d,  $J$  = 6.8 Hz, 1H), 4.46–4.41 (m, 2H), 2.72–2.67 (m, 2H), 2.37 (s, 3H), 1.43 (t,  $J$  = 7.2 Hz, 3H), 1.26 (t,  $J$  = 7.4 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  160.5, 148.8, 146.5, 144.2, 136.8, 129.5 (3C), 128.1 (2C), 127.3, 115.7, 114.4, 100.2, 61.0, 28.5, 21.7, 14.7, 14.2; IR (KBr)  $\nu$  2970, 1656, 1544, 1436, 1384, 1220, 1165, 1085, 864  $\text{cm}^{-1}$ ; HRMS (ESI) (*m/z*). Calcd for  $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_4\text{S}$ ,  $[\text{M} + \text{H}]^+$  388.1326, found 388.1326.

Ethyl-5-ethyl-2-((4-methylphenyl)sulfonamido)imidazo[1,2-a]pyridine-3-carboxylate (**4d**) (89.5 mg, 23%), yellow solid, m.p. = 105–107 °C ( $R_f$  = 0.25 in 1 : 4 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.84 (s, 1H), 8.05 (d,  $J$  = 8.0 Hz, 2H), 7.49 (d,  $J$  = 8.8 Hz, 1H), 7.38 (t,  $J$  = 7.8 Hz, 1H), 7.27 (d,  $J$  = 7.2 Hz, 2H), 6.80 (d,  $J$  = 6.8 Hz, 1H), 4.43–4.38 (m, 2H), 3.13–3.07 (m, 2H), 2.37 (s, 3H), 1.43 (t,  $J$  = 6.8 Hz, 3H), 1.20 (t,  $J$  = 7.2 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  159.7, 150.1, 148.3, 145.3, 144.1, 136.8, 129.5, 129.4 (2C), 128.3 (2C), 114.6, 113.5, 101.9, 61.3, 27.4, 21.7, 14.7, 11.3; IR (KBr)  $\nu$  3263, 2978, 1597, 1519, 1440, 1327, 1159, 1089, 812, 663  $\text{cm}^{-1}$ ; HRMS (ESI) (*m/z*). Calcd for  $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_4\text{S}$ ,  $[\text{M} + \text{H}]^+$  388.1326, found 388.1317.

Ethyl-8-methoxy-2-((4-methylphenyl)sulfonamido)imidazo[1,2-a]pyridine-3-carboxylate (**4e**) (202.4 mg, 52%), white solid, m.p. = 162–164 °C ( $R_f$  = 0.25 in 1 : 3 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.69 (s, 1H), 8.57 (d,  $J$  = 6.4 Hz, 1H), 8.11 (d,  $J$  = 8.0 Hz, 2H), 7.27 (d,  $J$  = 8.4 Hz, 2H), 6.83 (t,  $J$  = 7.4 Hz, 1H), 6.70 (d,  $J$  = 7.6 Hz, 1H), 4.46–4.41 (m, 2H), 3.99 (s, 3H), 2.37 (s, 3H), 1.43 (t,  $J$  = 7.2 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  160.6, 148.3, 148.0, 144.2, 139.9, 137.0, 129.4 (2C), 128.6 (2C), 120.6, 114.1, 106.5, 101.4, 61.1, 56.5, 21.8, 14.7; IR (KBr)  $\nu$  2983, 1656, 1544, 1452, 1267, 1159, 1089, 1012, 665  $\text{cm}^{-1}$ ; HRMS (ESI) (*m/z*). Calcd for  $\text{C}_{18}\text{H}_{19}\text{N}_3\text{O}_5\text{S}$ ,  $[\text{M} + \text{H}]^+$  390.1118, found 390.1112.

Ethyl-2-(phenylsulfonamido)imidazo[1,2-a]pyridine-3-carboxylate (**4f**) (303.8 mg, 88%), white solid, m.p. = 116–118 °C ( $R_f$  = 0.25 in 1 : 3 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.93 (s, 2H), 8.19 (d,  $J$  = 7.6 Hz, 2H), 7.59 (d,  $J$  = 8.8 Hz, 1H), 7.54 (t,  $J$  = 7.2 Hz, 1H), 7.47 (t,  $J$  = 7.4 Hz, 2H), 7.37 (t,  $J$  = 8.0 Hz, 1H), 6.95 (t,  $J$  = 6.8 Hz, 1H), 4.48–4.42 (m,

2H), 1.44 (t,  $J$  = 7.0 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  160.5, 149.0, 145.9, 139.7, 133.3, 128.8 (2C), 128.6, 128.2 (2C), 127.9, 117.0, 114.1, 100.3, 61.0, 14.7; IR (KBr)  $\nu$  3273, 2983, 1660, 1546, 1440, 1332, 1220, 1166, 1087  $\text{cm}^{-1}$ ; HRMS (ESI) (*m/z*). Calcd for  $\text{C}_{16}\text{H}_{15}\text{N}_3\text{O}_4\text{S}$ ,  $[\text{M} + \text{H}]^+$  346.0856, found 346.0851.

Ethyl-2-((4-chlorophenyl)sulfonamido)imidazo[1,2-a]pyridine-3-carboxylate (**4g**) (292.4 mg, 77%), white solid, m.p. = 141–143 °C ( $R_f$  = 0.3 in 1 : 3 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.94 (s, 2H), 8.15 (d,  $J$  = 8.0 Hz, 2H), 7.60 (d,  $J$  = 9.2 Hz, 1H), 7.45 (d,  $J$  = 8.0 Hz, 2H), 7.40 (t,  $J$  = 8.0 Hz, 1H), 6.97 (t,  $J$  = 6.6 Hz, 1H), 4.49–4.44 (m, 2H), 1.45 (t,  $J$  = 6.8 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  160.5, 148.8, 145.9, 139.8, 138.2, 129.8 (2C), 129.1 (2C), 128.7, 127.9, 117.0, 114.3, 100.4, 61.1, 14.7; IR (KBr)  $\nu$  3273, 2981, 1660, 1546, 1438, 1334, 1219, 1166, 1082  $\text{cm}^{-1}$ ; HRMS (ESI) (*m/z*). Calcd for  $\text{C}_{16}\text{H}_{14}\text{ClN}_3\text{O}_4\text{S}$ ,  $[\text{M} + \text{H}]^+$  380.0467, found 380.0460.

Ethyl-2-((4-bromophenyl)sulfonamido)imidazo[1,2-a]pyridine-3-carboxylate (**4h**) (318.2 mg, 75%), white solid, m.p. = 135–137 °C ( $R_f$  = 0.3 in 1 : 4 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) 8.94 (s, 2H), 8.07 (d,  $J$  = 8.0 Hz, 2H), 7.61 (t,  $J$  = 8.2 Hz, 3H), 7.40 (t,  $J$  = 7.8 Hz, 1H), 6.98 (t,  $J$  = 6.6 Hz, 1H), 4.49–4.44 (m, 2H), 1.45 (t,  $J$  = 6.8 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  160.5, 148.6, 143.9, 138.8, 132.1 (2C), 129.9 (2C), 128.7, 128.4, 127.9, 117.0, 114.3, 100.4, 61.2, 14.7; IR (KBr)  $\nu$  2964, 1658, 1546, 1438, 1330, 1217, 1147, 1085, 873, 759  $\text{cm}^{-1}$ ; HRMS (ESI) (*m/z*). Calcd for  $\text{C}_{16}\text{H}_{14}\text{BrN}_3\text{O}_4\text{S}$ ,  $[\text{M} - \text{H}]^-$  421.9815, found 421.9816.

Ethyl-2-((4-(trifluoromethyl)phenyl)sulfonamido)imidazo[1,2-a]pyridine-3-carboxylate (**4i**) (272.8 mg, 66%), yellow solid, m.p. = 160–162 °C ( $R_f$  = 0.25 in 1 : 3 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.94 (d,  $J$  = 6.4 Hz, 1H), 8.34 (d,  $J$  = 8.0 Hz, 2H), 7.75 (d,  $J$  = 8.0 Hz, 2H), 7.61 (d,  $J$  = 8.8 Hz, 1H), 7.42 (t,  $J$  = 7.8 Hz, 1H), 7.00 (t,  $J$  = 6.6 Hz, 1H), 4.50–4.45 (m, 2H), 1.46 (t,  $J$  = 7.0 Hz, 3H) (N–H signals obscured);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  160.5, 148.5, 145.8, 143.2, 135.0 (q,  $J$  = 32.8 Hz, 1C), 129.0, 128.8 (2C), 128.0, 126.0 (q,  $J$  = 3.8 Hz, 2C), 121.9 (q,  $J$  = 271.3 Hz, 1C), 117.0, 114.5, 100.6, 61.3, 14.7; IR (KBr)  $\nu$  3273, 2985, 1664, 1546, 1438, 1321, 1166, 1128, 1087, 1060  $\text{cm}^{-1}$ ; HRMS (ESI) (*m/z*). Calcd for  $\text{C}_{17}\text{H}_{14}\text{F}_3\text{N}_3\text{O}_4\text{S}$ ,  $[\text{M} + \text{H}]^+$  414.0730, found 414.0730.

Ethyl-2-((4-methoxyphenyl)sulfonamido)imidazo[1,2-a]pyridine-3-carboxylate (**4j**) (217.6 mg, 58%), yellow solid, m.p. = 135–137 °C ( $R_f$  = 0.3 in 1 : 2 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.95 (s, 1H), 8.79 (s, 1H), 8.12 (d,  $J$  = 8.0 Hz, 2H), 7.60 (d,  $J$  = 8.8 Hz, 1H), 7.37 (t,  $J$  = 8.0 Hz, 1H), 6.97–6.92 (m, 3H), 4.48–4.43 (m, 2H), 3.82 (s, 3H), 1.44 (t,  $J$  = 7.0 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  163.4, 160.5, 149.0, 146.0, 131.3, 130.5 (2C), 128.5, 127.9, 117.0, 114.1, 113.9 (2C), 100.3, 61.0, 55.6, 14.7; IR (KBr)  $\nu$  3363, 1685, 1546, 1442, 1325, 1219, 1159, 1085, 773  $\text{cm}^{-1}$ ; HRMS (ESI) (*m/z*). Calcd for  $\text{C}_{17}\text{H}_{17}\text{N}_3\text{O}_5\text{S}$ ,  $[\text{M} + \text{H}]^+$  376.0962, found 376.0956.

Ethyl-2-(methylsulfonamido)imidazo[1,2-a]pyridine-3-carboxylate (**4k**) (172.8 mg, 61%), yellow solid, m.p. = 145–147 °C ( $R_f$  = 0.22 in 1 : 2 v/v ethyl acetate/60–90 petroleum ether).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.05 (s, 1H), 8.49 (s, 1H), 7.64 (d,  $J$  = 8.8 Hz, 1H), 7.44 (t,  $J$  = 8.0 Hz, 1H), 7.02 (t,  $J$  = 7.0 Hz, 1H), 4.50–4.45 (m, 2H), 3.51 (s, 3H), 1.46 (t,  $J$  = 7.0 Hz, 3H);  $^{13}\text{C}$



NMR (100 MHz, CDCl<sub>3</sub>) δ 160.3, 149.1, 146.0, 128.9, 128.0, 116.8, 114.3, 100.3, 61.1, 42.1, 14.7; IR (KBr) ν 3294, 2983, 1662, 1546, 1438, 1328, 1219, 1153, 1085, 758 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>11</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 284.0700, found 284.0693.

Ethyl-2-(ethylsulfonamido)imidazo[1,2-*a*]pyridine-3-carboxylate (**4l**) (193.2 mg, 65%), brown solid, m.p. = 114–116 °C (*R<sub>f</sub>* = 0.20 in 1 : 4 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.05 (s, 1H), 8.37 (s, 1H), 7.64 (d, *J* = 8.8 Hz, 1H), 7.43 (t, *J* = 7.8 Hz, 1H), 7.02 (t, *J* = 6.8 Hz, 1H), 4.51–4.46 (m, 2H), 3.75–3.69 (m, 2H), 1.47–1.43 (m, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 160.4, 149.3, 146.0, 128.8, 128.0, 116.8, 114.3, 100.3, 61.1, 48.2, 14.7, 8.2; IR (KBr) ν 3363, 1685, 1546, 1440, 1325, 1219, 1157, 1085, 773 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 298.0856, found 298.0850.

Ethyl-2-(propylsulfonamido)imidazo[1,2-*a*]pyridine-3-carboxylate (**4m**) (236.5 mg, 76%), white solid, m.p. = 129–130 °C (*R<sub>f</sub>* = 0.30 in 1 : 4 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.04 (s, 1H), 8.40 (s, 1H), 7.63 (d, *J* = 8.8 Hz, 1H), 7.43 (t, *J* = 8.0 Hz, 1H), 7.01 (t, *J* = 6.8 Hz, 1H), 4.50–4.44 (m, 2H), 3.66 (t, *J* = 7.8 Hz, 2H), 1.99–1.90 (m, 2H), 1.45 (t, *J* = 7.2 Hz, 3H), 1.07 (t, *J* = 7.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 160.3, 149.2, 146.0, 128.8, 128.0, 116.8, 114.2, 100.2, 61.1, 55.4, 17.2, 14.2, 12.9; IR (KBr) ν 3363, 1685, 1544, 1440, 1365, 1325, 1274, 1219, 1157, 1085 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>13</sub>H<sub>17</sub>N<sub>3</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 312.1013, found 312.1006.

Ethyl-2-((2-methylpropyl)sulfonamido)imidazo[1,2-*a*]pyridine-3-carboxylate (**4n**) (214.6 mg, 66%), white solid, m.p. = 114–116 °C (*R<sub>f</sub>* = 0.30 in 1 : 2 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 9.30 (s, 1H), 9.10 (d, *J* = 6.8 Hz, 1H), 7.71 (d, *J* = 9.2 Hz, 1H), 7.59 (t, *J* = 8.0 Hz, 1H), 7.22 (t, *J* = 6.8 Hz, 1H), 4.41–4.36 (m, 2H), 3.57 (d, *J* = 6.4 Hz, 2H), 2.29–2.19 (m, 1H), 1.36 (t, *J* = 6.8 Hz, 3H), 1.05 (d, *J* = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 159.8, 147.8, 144.8, 129.3, 127.8, 116.2, 114.7, 101.0, 60.6, 60.4, 24.2, 22.1 (2C), 14.3; IR (KBr) ν 2964, 1658, 1546, 1438, 1330, 1217, 1147, 1085 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>14</sub>H<sub>19</sub>N<sub>3</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 326.1169, found 326.1163.

Methyl-2-((4-methylphenyl)sulfonamido)imidazo[1,2-*a*]pyridine-3-carboxylate (**4o**) (276.2 mg, 80%), white solid, m.p. = 144–146 °C (*R<sub>f</sub>* = 0.30 in 1 : 5 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.90 (s, 1H), 8.69 (s, 1H), 8.03 (d, *J* = 7.6 Hz, 2H), 7.54 (d, *J* = 8.8 Hz, 1H), 7.33 (t, *J* = 8.0 Hz, 1H), 7.22 (d, *J* = 7.6 Hz, 2H), 6.90 (t, *J* = 7.0 Hz, 1H), 3.93 (s, 3H), 2.32 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 160.7, 149.0, 146.0, 144.2, 136.8, 129.4 (2C), 128.6, 128.3 (2C), 127.9, 117.0, 114.1, 100.2, 51.8, 21.6; IR (KBr) ν 3282, 2954, 1691, 1664, 1544, 1450, 1332, 1222, 1163, 1085 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 346.0856, found 346.0850.

Tert-butyl 2-((4-methylphenyl)sulfonamido)imidazo[1,2-*a*]pyridine-3-carboxylate (**4p**) (329.3 mg, 85%), white solid, m.p. = 145–147 °C (*R<sub>f</sub>* = 0.25 in 1 : 6 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.87 (s, 2H), 8.01 (d, *J* = 8.0 Hz, 2H), 7.54 (d, *J* = 9.2 Hz, 1H), 7.30 (t, *J* = 8.0 Hz, 1H), 7.22 (d, *J* = 8.4 Hz, 2H), 6.88 (t, *J* = 6.8 Hz, 1H), 2.32 (s, 3H), 1.60 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 160.1, 148.7, 145.7, 144.1, 137.0, 129.8, 129.5 (2C), 128.2 (2C), 127.7, 117.0, 113.9, 101.2,

83.4, 28.7 (3C), 21.7; IR (KBr) ν 2978, 1658, 1544, 1438, 1334, 1263, 1165, 1085 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 388.1326, found 388.1317.

*N*-(3-acetylimidazo[1,2-*a*]pyridin-2-yl)-4-methylbenzene sulfonamide (**4q**) (256.8 mg, 78%), yellow solid, m.p. = 176–178 °C (*R<sub>f</sub>* = 0.25 in 1 : 1 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.36 (d, *J* = 7.2 Hz, 1H), 7.91 (d, *J* = 7.6 Hz, 2H), 7.86 (t, *J* = 7.8 Hz, 1H), 7.70 (d, *J* = 8.8 Hz, 1H), 7.41 (s, 1H), 7.27 (d, *J* = 7.6 Hz, 3H), 2.54 (s, 3H), 2.39 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 165.5, 152.0, 149.5, 142.5, 140.0, 137.0, 129.3 (2C), 128.5, 126.6 (2C), 126.4, 117.3, 103.2, 25.1, 21.5; IR (KBr) ν 3051, 1598, 1552, 1513, 1261, 1139, 1080, 827 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub>S, [M + H]<sup>+</sup> 330.0907, found 330.0902.

*N*-(3-Hexanoylimidazo[1,2-*a*]pyridin-2-yl)-4-methylbenzene sulfonamide (**4r**) (273.6 mg, 71%), brown solid, m.p. = 112–114 °C (*R<sub>f</sub>* = 0.25 in 1 : 1 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.39 (d, *J* = 7.2 Hz, 1H), 7.91 (d, *J* = 7.6 Hz, 2H), 7.84 (t, *J* = 7.8 Hz, 1H), 7.72 (d, *J* = 8.8 Hz, 1H), 7.39 (s, 1H), 7.27 (d, *J* = 7.2 Hz, 3H), 2.74 (t, *J* = 7.6 Hz, 2H), 2.39 (s, 3H), 1.76–1.67 (m, 2H), 1.32 (s, 4H), 0.89 (t, *J* = 6.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.4, 152.2, 149.6, 142.5, 140.0, 136.8, 129.3 (2C), 128.6, 126.7 (2C), 126.6, 117.2, 102.7, 38.7, 31.5, 28.4, 22.5, 21.6, 14.0; IR (KBr) ν 3118, 2926, 1598, 1550, 1415, 1280, 1139, 1080 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>20</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub>S, [M + H]<sup>+</sup> 386.1533, found 386.1525.

Ethyl-3-((6-methylpyridin-2-yl)amino)-3-(tosylimino)propanoate (**4s**) (93.9 mg, 25%), yellow solid, m.p. = 149–151 °C (*R<sub>f</sub>* = 0.25 in 1 : 4 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 10.94 (s, 1H), 7.85 (d, *J* = 8.0 Hz, 1H), 7.73–7.68 (m, 3H), 7.37 (d, *J* = 7.6 Hz, 2H), 7.06 (d, *J* = 7.2 Hz, 1H), 4.11–4.06 (m, 2H), 4.02 (s, 2H), 2.41 (s, 3H), 2.36 (s, 3H), 1.17 (t, *J* = 6.8 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 166.8, 158.3, 156.9, 150.0, 142.4, 139.9, 138.6, 129.4 (3C), 125.9 (2C), 120.2, 112.3, 60.9, 23.4, 20.9, 13.9; IR (KBr) ν 3286, 2983, 1737, 1597, 1541, 1452, 1280, 1145, 1087 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>18</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>S, [M + H]<sup>+</sup> 376.1326, found 376.1319.

Ethyl-3-((6-methoxypyridin-2-yl)amino)-3-(tosylimino)propanoate (**4t**) (234.6 mg, 60%), white solid, m.p. = 123–125 °C (*R<sub>f</sub>* = 0.25 in 1 : 4 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 10.74 (s, 1H), 7.71 (t, *J* = 9.2 Hz, 3H), 7.63 (d, *J* = 6.8 Hz, 1H), 7.37 (d, *J* = 7.6 Hz, 2H), 6.61 (d, *J* = 7.6 Hz, 1H), 4.12–4.05 (m, 4H), 3.83 (s, 3H), 2.37 (s, 3H), 1.18 (t, *J* = 6.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 166.9, 162.3, 158.3, 148.4, 142.5, 141.1, 139.8, 129.4 (3C), 126.0 (2C), 107.5, 106.9, 60.9, 53.2, 20.9, 13.9; IR (KBr) ν 3288, 2983, 1739, 1597, 1543, 1463, 1423, 1145, 1089, 1024 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>18</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub>S, [M + H]<sup>+</sup> 392.1275, found 392.1268.

4-Methyl-*N*-(3-(*m*-tolyl)imidazo[1,2-*a*]pyridin-2-yl)benzene sulfonamide (**4u**) (98.0 mg, 26%), brown solid, m.p. = 192–194 °C (*R<sub>f</sub>* = 0.25 in 1 : 2 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.74 (s, 1H), 8.09–8.03 (m, 2H), 7.66 (d, *J* = 7.2 Hz, 2H), 7.37 (d, *J* = 8.8 Hz, 1H), 7.26–7.25 (m, 3H), 7.21 (d, *J* = 7.2 Hz, 1H), 7.02 (t, *J* = 6.4 Hz, 1H), 6.98 (d, *J* = 7.2 Hz, 1H), 6.90 (s, 1H), 2.34 (s, 3H), 2.24 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 178.0, 162.5, 146.5, 141.4, 140.1, 138.0, 137.5, 135.4, 130.1, 128.62, 128.60 (2C), 126.9 (2C), 125.3,



122.1, 116.1, 115.7, 95.9, 21.0, 20.9; IR (KBr)  $\nu$  3057, 1747, 1566, 1467, 1336, 1278, 1145, 1082 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>S, [M + H]<sup>+</sup> 378.1271, found 378.1267.

*N*-(Pyridin-2-yl)-2-(*m*-tolyl)-*N'*-tosylacetimidamide (4v) (141.2 mg, 37%), yellow solid, m.p. = 103–105 °C (*R*<sub>f</sub> = 0.3 in 1 : 4 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.15 (s, 2H), 7.90 (d, *J* = 7.6 Hz, 2H), 7.59 (t, *J* = 7.6 Hz, 2H), 7.32–7.26 (m, 3H), 7.15–6.99 (m, 4H), 4.42 (s, 2H), 2.43 (s, 3H), 2.32 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.8, 150.2, 147.9, 142.9, 140.0, 139.5, 138.4, 132.5, 130.8, 129.6, 129.5 (2C), 129.3, 127.1, 126.6 (2C), 120.8, 115.4, 40.5, 21.6, 21.4; IR (KBr)  $\nu$  3358, 3278, 1597, 1566, 1527, 1435, 1280, 1143, 1085 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S, [M + H]<sup>+</sup> 380.1427, found 380.1421.

*2*-(4-Methoxyphenyl)-*N*-(pyridin-2-yl)-*N'*-tosylacetimidamide (4x) (130.5 mg, 33%), yellow solid, m.p. = 137–139 °C (*R*<sub>f</sub> = 0.3 in 1 : 2 v/v ethyl acetate/60–90 petroleum ether). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.17 (s, 1H), 8.11 (s, 1H), 7.90 (d, *J* = 7.6 Hz, 2H), 7.60 (t, *J* = 8.0 Hz, 1H), 7.50 (s, 1H), 7.32 (d, *J* = 7.6 Hz, 2H), 7.24 (t, *J* = 7.0 Hz, 2H), 7.01 (t, *J* = 5.8 Hz, 1H), 6.94 (d, *J* = 6.8 Hz, 2H), 4.42 (s, 2H), 3.81 (s, 3H), 2.44 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.2, 159.7, 150.2, 148.0, 142.9, 140.0, 138.4, 131.5, 129.5 (3C), 126.6 (3C), 124.2, 120.9, 115.3, 115.2, 55.4, 39.9, 21.6; IR (KBr)  $\nu$  3358, 2837, 1597, 1512, 1433, 1247, 1143, 1085 cm<sup>-1</sup>; HRMS (ESI) (*m/z*). Calcd for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>S, [M + H]<sup>+</sup> 396.1377, found 396.1369.

All NMR spectra please see ESI Section 3.†

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We thank the Foundation and Applied Basic Research Fund project of Guangdong Province of China (2019A1515110918); Science and Technology Planning Program of Zhanjiang (2021A05247); Medical Scientific Research Foundation of Guangdong Province (A2021037 and A2020202); Key Discipline Construction Project of Guangdong Medical University (4SG22004G); Innovation and Entrepreneurship Team Leads the Pilot Program of Zhanjiang (2020LHJH005) and the Science and technology program of Guangdong Province (2019B090905011) for support.

## Notes and references

- (a) U. B. Karale, A. U. Shinde, D. A. Babar, K. G. Sangu, S. K. Vagolu, V. K. Eruva, S. S. Jadav, S. Misra, S. Dharmarajan and H. B. Rode, *Arch. Pharm.*, 2021, **354**, e2000419; (b) A. Muthengi, V. K. Wimalasena, H. O. Yosief, M. J. Bikowitz, L. H. Sigua, T. Wang, D. Li, Z. Gaieb, G. Dhawan, S. Liu, J. Erickson, R. E. Amaro, E. Schönbrunn, J. Qi and W. Zhang, *J. Med. Chem.*, 2021, **64**, 5787; (c) A. K. Bagdi, S. Santra, K. Monir and A. Hajra, *Chem. Commun.*, 2015, **51**, 1555; (d) F. Zeng and M. M. Goodman, *Curr. Top. Med. Chem.*, 2013, **13**, 909; (e)

J. M. Monti, D. W. Spence, S. R. Pandi-Perumal, S. Z. Langer and R. Hardeland, *Clin. Med.: Ther.*, 2009, **1**, 123; (f) C. EnguehardGueiffier and A. Gueiffier, *Mini-Rev. Med. Chem.*, 2007, **7**, 888; (g) H. Heitsch, *Curr. Med. Chem.*, 2002, **9**, 913.

- (a) C. Wei, J. Huang, Y. Luo, S. Wang, S. Wu, Z. Xing and J. Chen, *Pestic. Biochem. Physiol.*, 2021, **175**, 104857; (b) O. Ebenezer, P. Awolade, N. Koobanally and P. Singh, *Chem. Biol. Drug Des.*, 2019, **1**; (c) N. M. Shukla, D. B. Salunke, E. Yoo, C. A. Mutz, R. Balakrishna and S. A. David, *Bioorg. Med. Chem.*, 2012, **20**, 5850; (d) T. H. Al-Tel, R. A. Al-Qawasmeh and R. Zaarour, *Eur. J. Med. Chem.*, 2011, **46**, 1874.

- (a) S. R. Sagar, D. P. Singh, R. D. Das, N. B. Panchal, V. Sudarsanam, M. Nivsarkar and K. K. Vasu, *Bioorg. Med. Chem.*, 2021, **36**, 116091; (b) R. N. Rao, B. Mm, B. Maiti, R. Thakuria and K. Chanda, *ACS Comb. Sci.*, 2018, **20**, 164; (c) R. B. Lacerda, C. K. F. de Lima, L. L. da Silva, N. C. Romeiro, A. L. P. Miranda, E. J. Barreiro and C. A. M. Fraga, *Bioorg. Med. Chem.*, 2009, **17**, 74.

- (a) A. Hartwich, N. Zdzienicka, D. Schols, G. Andrei, R. Snoeck and I. E. Głowacka, *Nucleosides, Nucleotides Nucleic Acids*, 2020, **39**, 542; (b) G. C. Moraski, L. D. Markley, P. A. Hipskind, H. Boshoff, S. Cho, S. G. Franzblau and M. J. Miller, *ACS Med. Chem. Lett.*, 2011, **2**, 466; (c) I. Vliegen, J. Paeshuyse, T. D. Burghgraeve, L. S. Lehman, M. Paulson, I.-H. Shih, E. Mabery, N. Boddeker, E. D. Clercq, H. Reiser, D. Oare, W. A. Lee, W. Zhong, S. Bondy, G. Pürstinger and J. Neyts, *J. Hepatol.*, 2009, **50**, 999; (d) K. S. Gudmundsson, J. D. Williams, J. C. Drach and L. B. Townsend, *J. Med. Chem.*, 2003, **46**, 1449.

- (a) D. C. D. Santos, J. Rafique, S. Saba, G. M. Almeida, T. Siminski, C. Pádua, D. W. Filho, A. Zamoner, A. L. Braga, R. C. Pedrosa and F. Ourique, *J. Biochem. Mol. Toxicol.*, 2021, **35**, e22663; (b) D. K. Sigalapalli, G. Kiranmai, G. P. Devi, R. Tokala, S. Sana, C. Tripura, G. S. Jadhav, M. Kadagathur, N. Shankaraiah, N. Nagesh, B. N. Babu and N. D. Tangellamudi, *Bioorg. Med. Chem.*, 2021, **43**, 116277; (c) M. Matsumura, T. Takahashi, H. Yamauchi, S. Sakuma, Y. Hayashi, T. Hyodo, T. Obata, K. Yamaguchi, Y. Fujiwara and S. Yasuike, *Beilstein J. Org. Chem.*, 2020, **16**, 1075; (d) J.-B. Xi, Y.-F. Fang, B. Frett, M.-L. Zhu, T. Zhu, Y.-N. Kong, F.-J. Guan, Y. Zhao, X.-W. Zhang, H.-Y. Li, M.-L. Ma and W. Hu, *Eur. J. Med. Chem.*, 2017, **126**, 1083; (e) O. Kim, Y. Jeong, H. Lee, S.-S. Hong and S. Hong, *J. Med. Chem.*, 2011, **54**, 2455.

- D. Dheer, K. R. Reddy, S. K. Rath, P. L. Sangwan, P. Das and R. Shankar, *RSC Adv.*, 2016, **6**, 38033.

- N. Chernyak and V. Gevorgyan, *Angew. Chem.*, 2010, **122**, 2803.

- (a) A. N. Edinoff, N. Wu, Y. T. Ghaffar, R. Prejean, R. Gremillion, M. Cogburn, A. A. Chami, A. M. Kaye and A. D. Kaye, *Health. Psychol. Res.*, 2021, **9**, 24927; (b) G. Richter, V. W. Y. Liao, P. K. Ahring and M. Chebib, *Front. Neurosci.*, 2020, **14**, 599812; (c) R. Rosenberg, P. Murphy, G. Zammit, D. Mayleben, D. Kumar, S. Dhadda,



- G. Filippov, A. LoPresti and M. Moline, *JAMA Netw. Open*, 2019, **2**, e1918254.
- 9 K. Bagdi, M. Rahman, S. Santra, A. Majee and A. Hajra, *Adv. Synth. Catal.*, 2013, **355**, 1741.
- 10 (a) A. Heidari, *J. Data Min. Genomics Proteomics*, 2016, **7**, e125; (b) Y. Maruyama, K. Anami, M. Terasawa, K. Goto, T. Imayoshi, Y. Kadobe and Y. Mizushima, *Arzneimittelforschung*, 1981, **31**, 1111.
- 11 Y. Abe, H. Kayakiri, S. Satoh, T. Inoue, Y. Sawada, N. Inamura, M. Asano, I. Aramori, C. Hatori, H. Sawai, T. Oku and H. Tanaka, *J. Med. Chem.*, 1998, **41**, 4587.
- 12 (a) Y. Wu, L. Li, K. Wen, J. Deng, J. Chen, J. Shi, T. Wu, J. Pang and X. Tang, *J. Org. Chem.*, 2021, **86**, 12394; (b) R. Semwal, C. Ravi, S. Saxena and S. Adimurthy, *J. Org. Chem.*, 2019, **84**, 14151; (c) K. Sun, S. Mu, Z. Liu, R. Feng, Y. Li, K. Pang and B. Zhang, *Org. Biomol. Chem.*, 2018, **16**, 6655.
- 13 (a) R. Semwal, G. Badhani and S. Adimurthy, *Chem. Commun.*, 2022, **58**, 1585; (b) X. Chen, P. Sun, B. Mo, C. Chen and J. Peng, *J. Org. Chem.*, 2021, **86**, 352; (c) J. A. Tali, G. Kumar, D. Singh and R. Shankar, *Org. Biomol. Chem.*, 2021, **19**, 9401; (d) A. Joshi, R. Semwal, E. Suresh and S. Adimurthy, *Chem. Commun.*, 2019, **55**, 10888.
- 14 (a) H. Yao, X. Zhong, B. Wang, S. Lin, L. Liu and Z. Yan, *Org. Biomol. Chem.*, 2021, **19**, 3479; (b) J. Rakhtshah and F. Yaghoobi, *Int. J. Biol. Macromol.*, 2019, **139**, 904.
- 15 D. S. Nipate, S. Jaspal, V. N. Shinde, K. Rangan and A. Kumar, *Org. Lett.*, 2021, **23**, 1373.
- 16 Z. Hu, J. Hou, J. Liu, W. Yu and J. Chang, *Org. Biomol. Chem.*, 2018, **16**, 5653.
- 17 (a) F. Vuillermet, J. Bourret and G. Pelletier, *J. Org. Chem.*, 2021, **86**, 388; (b) Y. Yuan, Z. Zhou, L. Zhang, L. S. Li and A. Lei, *Org. Lett.*, 2021, **23**, 5932.
- 18 (a) R. Semwal, C. Ravi, R. Kumar, R. Meena and S. Adimurthy, *J. Org. Chem.*, 2019, **84**, 792; (b) R. Q. Tran, S. A. Jacoby, K. E. Roberts, W. A. Swann, N. W. Harris, L. P. Dinh, E. L. Denison and L. Yet, *RSC Adv.*, 2019, **9**, 17778; (c) Y. Liu, W. Wang, J. Han and J. Sun, *Org. Biomol. Chem.*, 2017, **15**, 9311; (d) S. Samanta, S. Jana, S. Mondal, K. Monir, S. K. Chandra and A. Hajra, *Org. Biomol. Chem.*, 2016, **14**, 5073; (e) D. Dheer, K. R. Reddy, S. K. Rath, P. L. Sangwan, P. Das and R. Shankar, *RSC Adv.*, 2016, **6**, 38033; (f) X. Xiao, Y. Xie, S. Bai, Y. Deng, H. Jiang and W. Zeng, *Org. Lett.*, 2015, **17**, 3998.
- 19 (a) H. D. de Salles, T. L. da Silva, C. S. Radatz, R. F. Affeldt, E. V. Benvenutti and P. H. Schneider, *J. Braz. Chem. Soc.*, 2019, **30**, 1825; (b) J. B. Bharate, S. K. Guru, S. K. Jain, S. Meena, P. P. Singh, S. Bhushan, B. Singh, S. B. Bharate and R. A. Vishwakarma, *RSC Adv.*, 2013, **3**, 20869; (c) S. K. Guchhait, A. L. Chandgude and G. Priyadarshani, *J. Org. Chem.*, 2012, **77**, 4438; (d) H. Yan, R. Yan, S. Yang, X. Gao, Y. Wang, G. Huang and Y. Liang, *Chem.-Asian J.*, 2012, **7**, 2028; (e) T. Palani, K. Park, M. R. Kumar, H. M. Jung and S. Lee, *Eur. J. Org. Chem.*, 2012, 5038; (f) S. Mishra and R. Ghosh, *Synlett*, 2011, 3463; (g) N. Chernyak and V. Gevorgyan, *Angew. Chem., Int. Ed.*, 2010, **49**, 2743; (h) P. Liu, L. Fang, X. Lei and G. Lin, *Tetrahedron Lett.*, 2010, **51**, 4605.
- 20 (a) S. Bahadorikhilili, M. Divar, T. Damghani, F. Moeini, S. Ghassamipour, A. Iraji, M. A. Miller, B. Larijani and M. Mahdavi, *J. Organomet. Chem.*, 2021, **939**, 121773; (b) S. H. Kim, S. H. Park, J. H. Choi and S. Chang, *Chem.-Asian J.*, 2011, **6**, 2618; (c) I. Bae, H. Han and S. Chang, *J. Am. Chem. Soc.*, 2005, **127**, 2038; (d) S. H. Cho, E. J. Yoo, I. Bae and S. Chang, *J. Am. Chem. Soc.*, 2005, **127**, 16046.
- 21 (a) C. Nájera, L. K. Sydnes and M. Yus, *Chem. Rev.*, 2019, **119**, 11110; (b) M. Nallagangula and K. Namitharan, *Org. Lett.*, 2017, **19**, 3536; (c) C. Shao, Q. Zhang and G. Cheng, *Eur. J. Org. Chem.*, 2013, **2013**, 6443; (d) P. V. Ramachandran, M. T. Rudd and M. V. R. Reddy, *Tetrahedron Lett.*, 2005, **46**, 2547.
- 22 (a) W. Yang, Y. Zhao, Q. Bu, L. Li, B. Zhou and Z. Huang, *Org. Lett.*, 2022, **24**, 457; (b) Y. Zhao, L. Li, Z. Zhou, M. Chen, W. Yang and H. Luo, *Org. Biomol. Chem.*, 2021, **19**, 3868; (c) X. Luo, Y. Zhao, S. Tao, Z.-T. Yang, H. Luo and W. Yang, *RSC Adv.*, 2021, **11**, 31152; (d) W. Yang, D. Huang, X. Zeng, J. Zhang, X. Wang and Y. Hu, *Tetrahedron*, 2019, **75**, 381; (e) W. Yang, D. Huang, X. Zeng, D. Luo, X. Wang and Y. Hu, *Chem. Commun.*, 2018, **54**, 8222.
- 23 X. Li, *J. Chem. Res.*, 2012, **36**, 525.

